James E. Crowe, MD

James E. Crowe, MD

Professor of Pediatrics and Pathology, Microbiology and Immunology
Pediatric Infectious Diseases
Vanderbilt Vaccine Center
Ann Scott Carell Chair
Department of Pediatrics
Medical Center North
1161 21st Avenue South
Room / Suite
(615) 343-8064

Infectious Diseases, Pediatric
University of North Carolina, 1987
Residency in Pediatrics-University of North Carolina Chapel Hill, NC
Medical Staff Fellow in Virology-National Institutes of Health, Bethesda, MD
Clinical Fellowship, Pediatric Infectious Diseases-Vanderbilt University Medical Center, Nashville, TN

Clinical Interests

Emerging viral infections

Research Information

Dr. Crowe is Director of the Vanderbilt Vaccine Center, the Ann Scott Carell Professor of Pediatrics, Pathology, Microbiology and Immunology, and University Distinguished Professor of Chemistry. His laboratory studies the human immune response to infection for a wide variety of major human pathogens, including many emerging infections. He is an elected member of the National Academy of Medicine, National Academy of Inventors, and other major professional organizations. His work has been recognized by a number of international awards, including the The Harrington Prize for Innovation in Medicine, the Golden Goose Award, the Judson Daland Prize of the American Philosophical Society, the Oswald Avery Award of the IDSA, and the Korsmeyer Award of the American Society for Clinical Investigation. This research group uses a very broad array of techniques including molecular and cellular biology, state-of-the-art imaging and flow cytometry, bioinformatics, and bioengineering approaches to attack scientific problems at the forefront of immunity research. The group has been recognized widely as a leader in antibody sciences, for instance as the Best Academic Research Team, 11th Annual Vaccine Industry Excellence Awards, World Vaccine Congress, recipient of the 2019 Merck Future Insight Prize, and large-scale research grants and contracts from NIH and DoD, including the DARPA Pandemic Prevention Program (P3). His team developed the COVID-19 antibodies on which Evusheld (tixagevimab + cilgavimab) is based.

>> View Publications on PubMed